New approaches to vaccination (Q57170110)

https://api.crossref.org/works/10.1002/9781118636817.CH21

Vaccinate for the next H2N2 pandemic now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structure of a Classical Broadly Neutralizing Stem Antibody in Complex with a Pandemic H2 Influenza Virus Hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

The structure and receptor binding properties of the 1918 influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Cross-neutralization of influenza A viruses mediated by a single antibody loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

DNA vaccines against influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

DNA Immunization for Influenza Virus: Studies Using Hemagglutinin‐ and Nucleoprotein‐Expressing DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Structural and genetic basis for development of broadly neutralizing influenza antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Highly Conserved Protective Epitopes on Influenza B Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21

Vaccinate before the next pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/9781118636817.CH21